| Literature DB >> 24143082 |
Suzana Shahar1, Norshafarina Shari Kamaruddin, Manal Badrasawi, Noor Ibrahim Mohamed Sakian, Zahara Abd Manaf, Zaitun Yassin, Leonard Joseph.
Abstract
Sarcopenia, characterized as muscle loss that occurs with aging, is a major health problem in an aging population, due to its implications on mobility, quality of life, and fall risk. Protein supplementation could improve the physical fitness by increasing protein anabolism, and exercise has a documented evidence of positive effect on functional status among the elderly. However, the combined effect of both protein supplementation and exercise has not been investigated among sarcopenic elderly in the Asian population. Thus, this study aimed to determine the effectiveness of exercise intervention and protein supplementation either alone or in combination for 12 weeks, on body composition, functional fitness, and oxidative stress among elderly Malays with sarcopenia. Sixty five sarcopenic elderly Malays aged 60-74 years were assigned to the control group, exercise group (ExG), protein supplementation group (PrG), or the combination of exercise and protein supplementation group. A significant interaction effect between body weight and body mass index (BMI) was observed, with the PrG (-2.1% body weight, -1.8% BMI) showing the highest reductions. Further, there was a decrease in % body fat (-4.5%) and an increase in fat-free mass (kg) (+5.7%) in the ExG after 12 weeks (P < 0.05). The highest increments in lower and upper body strength were observed in the PrG (73.2%) and ExG (47.6%), respectively. In addition, the ExG showed a reduction in superoxide dismutase (SOD) levels, and both interventions did not alter either lipid or protein oxidation. In conclusion, the exercise program was found to improve muscle strength and body composition, while protein supplementation reduced body weight and increased upper body strength, among sarcopenic elderly in Malaysia.Entities:
Keywords: Asian; Malaysia; aging population; protein supplement; sarcopenic elderly
Mesh:
Substances:
Year: 2013 PMID: 24143082 PMCID: PMC3797615 DOI: 10.2147/CIA.S46826
Source DB: PubMed Journal: Clin Interv Aging ISSN: 1176-9092 Impact factor: 4.458
Baseline characteristic according to intervention group
| Baseline characteristics | Study groups
| ANCOVA (two-way)
| |||
|---|---|---|---|---|---|
| CG | ExG | PrG | ExG+PrG | ||
| Age (year) | 67.25 ± 5.48 | 69.74 ± 5.46 | 65.93 ± 4.37 | 65.20 ± 4.87 | 0.083 |
| Weight (kg) | 67.36 ± 11.88 | 60.49 ± 10.66 | 61.39 ± 12.73 | 65.53 ± 12.40 | 0.203 |
| BMI (kg/m2) | 26.36 ± 3.19 | 23.71 ± 3.46 | 24.26 ± 4.37 | 26.47 ± 4.75 | 0.103 |
| Body fat (%) | 28.82 ± 6.89 | 25.25 ± 6.57 | 27.51 ± 9.17 | 31.97 ± 9.62 | 0.079 |
| FFM (kg) | 48.68 ± 8.1 | 44.4 ± 7.4 | 44.0 ± 8.1 | 43.9 ± 7.7 | 0.276 |
| Muscle (kg) | 22.94 ± 5.29 | 20.95 ± 4.23 | 20.57 ± 4.70 | 20.73 ± 4.69 | 0.462 |
| Body water (%) | 55.77 ± 4.04 | 57.91 ± 3.42 | 56.29 ± 4.96 | 53.75 ± 5.17 | 0.370 |
| IADl score | 7.59 ± 0.88 | 7.37 ± 0.89 | 8.00 ± 0.00 | 7.53 ± 0.64 | 0.094 |
| IPAQ score | 1699.35 ± 153.49 | 1330.48 ± 954.33 | 1467.20 ± 842.66 | 1479.18 ± 724.35 | 0.691 |
| Calorie (Kcal) | 1377.76 ± 153.49 | 1452.70 ± 192.91 | 1320.86 ± 111.43 | 1377.76 ± 153.49 | 0.132 |
| Carbohydrate (Kcal) | 191.75 ± 27.10 | 225.81 ± 35.55 | 187.80 ± 22.89 | 199.23 ± 22.65 | 0.001 |
| Protein (g) | 61.07 ± 9.32 | 54.89 ± 8.86 | 49.96 ± 11.70 | 55.63 ± 5.85 | 0.014 |
| Fat (g) | 40.79 ± 10.39 | 36.05 ± 4.72 | 41.15 ± 6.40 | 39.32 ± 10.91 | 0.261 |
Notes: Values are expressed as mean ± SD.
P < 0.05 is significant with baseline measurement used as covariates on ANCOVA analysis.
Abbreviations: ANCOVA, analysis of covariance; BMI, body mass index; CG, control group; ExG, exercise group; ExG+PrG, combined exercise and protein supplementation group; FFM, fat-free mass; IADL, instrumental activity of daily living; IPAQ, international physical activity questionnaire; PrG, protein suplementation group; SD, standard deviation.
Profile of anthropometry and body composition at baseline, 6 weeks, and 12 weeks of intervention, according to intervention group
| Anthropometric measurement | Study groups
| ANCOVA (two-way)
| |||||
|---|---|---|---|---|---|---|---|
| CG | ExG | PrG | ExG+PrG | Group effect | Time effect | Interaction effect | |
| Weight (kg) | |||||||
| Baseline | 67.36 ± 11.88 | 59.49 ± 10.66 | 61.39 ± 12.73 | 65.53 ± 12.40 | 0.404 | 0.083 | 0.027) |
| 6 weeks | 63.98 ± 10.44 | 59.03 ± 10.28 | 63.12 ± 11.16 | 66.43 ± 12.56 | (0.048) | (0.041) | (0.112) |
| 12 weeks | 65.99 ± 10.85 | 59.78 ± 10.89 | 60.11 ± 11.48 | 66.18 ± 12.70 | |||
| BMI (kg/m2) | |||||||
| Baseline | 26.36 ± 3.19 | 23.71 ± 3.46 | 24.26 ± 4.37 | 26.47 ± 4.75 | 0.315 | 0.029 | 0.041 |
| 6 weeks | 25.31 ± 2.47 | 23.38 ± 3.03 | 24.87 ± 3.48 | 26.47 ± 4.52 | (0.058) | (0.058) | (0.104) |
| 12 weeks | 25.91 ± 2.96 | 23.93 ± 3.61 | 23.82 ± 4.16 | 26.45 ± 4.65 | |||
| Body fat (%) | |||||||
| Baseline | 28.82 ± 6.89 | 25.25 ± 6.57 | 27.51 ± 9.17 | 31.97 ± 9.62 | 0.332 | 0.480 | 0.023 |
| 6 weeks | 25.67 ± 8.38 | 24.32 ± 6.34 | 28.41 ± 9.89 | 29.69 ± 10.89 | (0.056) | (0.012) | (0.115) |
| 12 weeks | 27.83 ± 6.99 | 22.32 ± 9.93 | 27.37 ± 10.30 | 32.28 ± 9.64 | |||
| FFM (kg) | |||||||
| Baseline | 48.60 ± 8.07 | 44.38 ± 7.38 | 44.02 ± 8.14 | 43.96 ± 7.74 | 0.209 | 0.184 | 0.005 |
| 6 weeks | 46.38 ± 8.15 | 45.04 ± 7.73 | 44.67 ± 7.52 | 46.08 ± 8.72 | (0.073) | (0.028) | (0.143) |
| 12 weeks | 47.73 ± 7.39 | 46.74 ± 8.13 | 43.09 ± 7.61 | 44.09 ± 8.57 | |||
| Muscle (kg) | |||||||
| Baseline | 22.94 ± 5.29 | 20.95 ± 4.23 | 20.57 ± 4.70 | 20.73 ± 4.69 | 0.574 | 0.384 | 0.111 |
| 6 weeks | 20.98 ± 5.27 | 20.82 ± 4.23 | 21.49 ± 4.11 | 21.98 ± 5.26 | (0.033) | (0.016) | (0.083) |
| 12 weeks | 22.68 ± 4.22 | 21.29 ± 4.64 | 20.29 ± 4.31 | 21.02 ± 5.11 | |||
| Body water (%) | |||||||
| Baseline | 55.05 ± 4.04 | 57.91 ± 3.42 | 56.29 ± 4.96 | 53.75 ± 5.17 | 0.006 | 0.036 | 0.000 |
| 6 weeks | 63.83 ± 13.84 | 58.22 ± 3.62 | 52.92 ± 8.75 | 55.73 ± 6.08 | (0.190) | (0.055) | (0.240) |
| 12 weeks | 56.31 ± 3.51 | 65.46 ± 12.21 | 55.59 ± 5.68 | 53.27 ± 4.87 | |||
Notes: Values are expressed as mean ± SD.
P < 0.05 significant effect using ANCOVA, with sarcopenia status and sex as covariates.
Abbreviations: ANCOVA, analysis of covariance; BMI, body mass index; CG, control group; ExG, exercise group; ExG+PrG, combined exercise and protein supplementation group; FFM, fat-free mass; PrG, protein suplementation group; SD, standard deviation.
Functional fitness test at baseline, 6 weeks, and 12 weeks of intervention, according to intervention groups
| Functional fitness test | Study groups
| ANCOVA (two-way)
| |||||
|---|---|---|---|---|---|---|---|
| CG | ExG | PrG | ExG+PrG | Group effect | Time effect | Interaction effect | |
| Chair Stand Test (times) | |||||||
| Baseline | 11.23 ± 4.44 | 14.29 ± 4.95 | 9.60 ± 2.26 | 10.32 ± 3.01 | 0.000 | 0.000 | 0.002 |
| 6 weeks | 12.15 ± 3.37 | 16.19 ± 4.67 | 11.42 ± 2.41 | 16.53 ± 3.31 | (0.280) | (0.161) | (0.165) |
| 12 weeks | 12.39 ± 4.17 | 17.69 ± 6.54 | 16.63 ± 3.03 | 16.80 ± 3.93 | |||
| Arm Curl Test (times) | |||||||
| Baseline | 18.39 ± 5.88 | 12.20 ± 3.42 | 11.47 ± 2.89 | 13.39 ± 2.25 | |||
| 6 weeks | 19.92 ± 8.42 | 23.17 ± 6.73 | 15.95 ± 3.37 | 24.87 ± 6.16 | 0.033 | 0.001 | 0.001 |
| 12 weeks | 16.37 ± 4.02 | 18.01 ± 5.70 | 15.68 ± 2.52 | 18.53 ± 3.76 | (0.186) | (0.109) | (0.181) |
| Chair Sit and Reach (mm) | |||||||
| Baseline | 5.87 ± 12.85 | 5.17 ± 11.98 | 1.52 ± 14.07 | −3.27 ± 10.00 | |||
| 6 weeks | 5.29 ± 3.06 | 11.16 ± 6.48 | 3.43 ± 11.68 | 2.57 ± 7.81 | 0.065 | 0.576 | 0.414 |
| 12 weeks | 0.32 ± 10.50 | 2.60 ± 8.43 | −2.53 ± 7.76 | −1.40 ± 8.53 | (0.114) | (0.009) | (0.049) |
| Backscratch (mm) | |||||||
| Baseline | −9.98 ± 16.67 | −2.02 ± 12.16 | −11.89 ± 13.19 | −10.36 ± 10.38 | |||
| 6 weeks | −13.53 ± 11.39 | −9.82 ± 9.70 | −10.89 ± 14.41 | −2.03 ± 17.84 | 0.252 | 0.542 | 0.112 |
| 12 weeks | −20.07 ± 12.66 | −16.83 ± 9.65 | −18.18 ± 8.45 | −20.27 ± 12.38 | (0.066) | (0.010) | (0.082) |
| 8-Foot Up and Go (s) | |||||||
| Baseline | 7.34 ± 2.36 | 8.54 ± 2.41 | 8.26 ± 1.91 | 8.39 ± 0.83 | |||
| 6 weeks | 7.39 ± 1.61 | 6.55 ± 1.20 | 7.73 ± 1.38 | 5.95 ± 1.44 | 0.336 | 0.567 | 0.016 |
| 12 weeks | 8.65 ± 5.53 | 6.69 ± 1.85 | 5.92 ± 4.92 | 6.16 ± 1.39 | (0.055) | (0.010) | (0.122) |
| Six-minute Walk (m) | |||||||
| Baseline | 343.48 ± 117.99 | 360.66 ± 162.03 | 335.97 ± 87.63 | 321.17 ± 49.75 | |||
| 6 weeks | 349.38 ± 88.19 | 400.82 ± 85.07 | 380.31 ± 63.80 | 366.86 ± 54.83 | 0.462 | 0.481 | 0.939 |
| 12 weeks | 359.18 ± 152.93 | 412.71 ± 136.49 | 360.71 ± 93.23 | 377.23 ± 53.96 | (0.042) | (0.012) | (0.015) |
| Handgrip Strength (kg) | |||||||
| Baseline | 21.42 ± 8.41 | 20.37 ± 5.64 | 19.75 ± 9.02 | 20.80 ± 8.23 | |||
| 6 weeks | 19.53 ± 6.85 | 20.18 ± 5.49 | 18.02 ± 7.03 | 24.33 ± 7.68 | 0.140 | 0.124 | 0.167 |
| 12 weeks | 18.64 ± 5.46 | 19.03 ± 6.32 | 16.87 ± 7.61 | 19.27 ± 6.92 | (0.088) | (0.035) | (0.073) |
Notes: Values are expressed as mean ± SD.
P < 0.05 significant effect using ANCOVA with sarcopenia status and sex as covariates.
Abbreviations: ANCOVA, analysis of covariance; CG, control group; ExG, exercise group; ExG+PrG, combined exercise and protein supplementation group; PrG, protein suplementation group; SD, standard deviation.
Figure 1Percent changes in Chair Stand Test results, in the different intervention groups during the 12-week intervention.
Notes: Values are expressed as mean ± SD. *Significant differences at P < 0.05 from baseline.
Abbreviations: CG, control group; ExG, exercise group; ExG+PrG, combined exercise and protein supplementation group; PrG, protein suplementation group; SD, standard deviation; s, seconds.
Figure 2Percent changes in Arm Curl Test results, in the different intervention groups during the 12-week intervention.
Notes: Values are expressed as mean ± SD. *Significant differences at P < 0.05 from baseline.
Abbreviations: CG, control group; ExG, exercise group; ExG+PrG, combined exercise and protein supplementation group; PrG, protein suplementation group; SD, standard deviation; s, seconds.
Figure 3Percent changes in 8-Foot Up and Go Test results, in the different intervention groups during the 12-week intervention.
Notes: Values are expressed as mean ± SD. *Significant differences at P < 0.05 from baseline.
Abbreviations: CG, control group; ExG, exercise group; ExG+PrG, combined exercise and protein supplementation group; PrG, protein suplementation group; SD, standard deviation.
Measurement of oxidative stress markers at baseline, 6 weeks, and 12 weeks, according to intervention group
| Intervention group
| ANCOVA (two way)
| ||||||
|---|---|---|---|---|---|---|---|
| Control | Exercise | Protein supplementation | Exercise + protein supplementation | Group effect | Time effect | Interaction effect | |
| Protein carbonyl (nmol/L) | |||||||
| Baseline | 0.03 ± 0.01 | 0.02 ± 0.01 | 0.02 ± 0.01 | 0.02 ± 0.01 | 0.039 | 0.026 | 0.092 |
| 6 weeks | 0.02 ± 0.01 | 0.02 ± 0.02 | 0.02 ± 0.01 | 0.01 ± 0.01 | (0.133) | (0.061) | (0.088) |
| 12 weeks | 0.02 ± 0.01 | 0.02 ± 0.02 | 0.02 ± 0.01 | 0.01 ± 0.01 | |||
| Superoxide dismutase (specific activity) | |||||||
| Baseline | 7.4 × 10−4 ± 4.4 ×10−4 | 10.2 × 10−4 ± 5.3 × 10−4 | 5.7 × 10−4 ± 2.6 × 10−4 | 6.3 × 10−4 ± 1.7 ×10−4 | 0.169 | 0.000 | 0.000 |
| 6 weeks | 8.2 × 10−4 ± 4.6 × 10−4 | 6.2 × 10−4 ± 2.8 × 10−4 | 8.1 × 10−4 ± 2.8 × 10−4 | 6.9 × 10−4 ± 3.7 × 10−4 | (0.083) | (0.138) | (0.236) |
| 12 weeks | 9.1 × 10−4 ± 3.5 × 10−4 | 6.3 × 10−4 ± 3.7 × 10−4 | 10.9 × 10−4 ± 3.7 × 10−4 | 6.3 × 10−4 ± 2.6 × 10−4 | |||
| Lipid hydroperoxide (mmol/L) | |||||||
| Baseline | 3.48 ± 1.07 | 2.54 ± 0.66 | 3.50 ± 1.09 | 1.49 ± 1.59 | 0.010a | 0.044a | 0.180 |
| 6 weeks | 2.05 ± 1.63 | 3.03 ± 1.37 | 3.64± 1.19 | 2.85 ± 1.75 | (0.175) | (0.053) | (0.073) |
| 12 weeks | 2.15 ± 1.27 | 2.41 ± 1.07 | 2.83 ± 0.78 | 2.71 ± 1.14 | |||
| IL-6 (pg/mL) | |||||||
| Baseline | 2.45 ± 1.29 | 1.89 ± 0.64 | 2.22 ± 0.59 | 2.49 ± 0.67 | 0.792 | 0.912 | 0.385 |
| 12 weeks | 1.76 ± 0.74 | 1.87 ± 0.82 | 1.97 ± 1.06 | 1.93 ± 0.83 | (0.017) | (0.000) | (0.050) |
| IGF-I (pg/mL) | |||||||
| Baseline | 91.31 ±33.79 | 80.96 ± 26.77 | 78.11 ±29.89 | 81.28 ± 17.32 | 0.197 | 0.254 | 0.806 |
| 12 weeks | 98.74 ± 17.65 | 91.81 ± 32.14 | 77.3 1 ± 25.03 | 91.06 ± 34.88 | (0.076) | (0.022) | (0.016) |
| Orexin (ng/mL) | |||||||
| Baseline | 0.42 ± 0.12 | 0.66 ± 0.19 | 0.34 ± 0.16 | 0.49 ± 0.10 | 0.593 | 0.073 | 0.593 |
| 12 weeks | 0.31 ± 0.21 | 0.28 ± 0.19 | 0.28 ± 0.3 1 | 0.29 ± 0.14 | (0..032) | (0.054) | (0.032) |
Notes: Values are expressed as mean + SD.
P < 0.05 significant effect using ANCOVA with sarcopenia status and sex as covariates.
Abbreviations: ANCOVA, analysis of covariance; IGF, insulin-like growth factor; IL, interleukin.